SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Maximize ARDS Ventilator Patient Recovery with APRV Strategy

fstapleton avatar
fstapleton
21 diapositives · 250 Views · Jan 01, 2020

Explore the evidence, limitations, and conclusions of APRV usage in ARDS patients to optimize ventilator strategies and enhance recovery outcomes for critically ill individuals with acute respiratory distress syndrome.

#maximize ards ventilator patient recovery with aprv strategy #maximize ards ventilator patient recovery with aprv strategy ppt #powerpoint #presentation
Maximize ARDS Ventilator Patient Recovery with APRV Strategy - slide 1
01 / 21Maximize ARDS Ventilator Patient Recovery with APRV Strategy
1 / 17

Télécharger la présentation

Maximize ARDS Ventilator Patient Recovery with APRV Strategy
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Con Position: APRV should be used in ARDS Timothy Scialla, MD Assistant Professor Division of Pulmonary and Critical Care Duke University 09/07/2017

  2. COI disclosure slide • I am a co-investigator for on-site clinical research trials sponsored by: • GSK • AstraZeneca • Sanofi • Genentech • NHLBI

  3. ARDS epidemiology • 190,000 cases / year in the USA • 50% Moderate (PaO2/FiO2 100-200) • 25% Severe (PaO2/FiO2 < 100) • Mortality 40% • Early (underlying cause) • Late (sepsis / nosocomial pneumonia /MODS) • Ventilatory failure (ie. Hypoxemia) uncommon • High Morbidity (cognitive, psychological, physical)

  4. The ARDS Industrial Complex • Nearly 2 decades of well-funded research • Multiple large randomized trials • Pharmacotherapy • Ventilator strategies • Hemodynamic monitoring/management • Lessons learned • Heterogeneous disease process • Different ARDS phenotypes • Few successes Extensive Animal Studies

  5. Studies with mortality benefit • ARMA trial • Neuromuscular blockade in ARDS • Prone positioning in ARDS • All three: • Avoid ventilator-induced lung injury

  6. The ventilator is an agent of harm Risk of overdistension injury 12 12 Lung volume 6 6 6 6 Risk of atelectasis injury Time

  7. Lung Protective Strategies • “Low VT” strategy • Minimize stress and strain • Limit VT and plateau pressure (<30cm H20) • “Open Lung” strategy: • recruiting nonaerated lung regions • Keep open with adequate levels of PEEP. • Minimize hyperinflation and atelectrauma with alveolar recruitment.

  8. ARDS Network Low vs. Traditional VT P=0.007 6 ml/kg 12 ml/kg • Absolute risk reduction = 9% (31% vs 40% mort) • Relative risk reduction = 22% Lower oxygenation Worse ventilation ARDS Network NEJM 2000

  9. Lung Protective Ventilation and Knowledge Translation Needham et al. BMJ. 2012 • 180/485 patients (37%) never had LPV • 417/485 (86%) adherent 50% or less

  10. NMB in early ARDS. Papazian et. al. NEJM. 2010 • 340 patients randomized • Sedative: Ramsey Level = 6 (very very sedated) • Cisatracurium group: • 15mg bolus followed by continuous infusion for 48hrs • Open label 20mg IV bolus of cisatracurium allowed in either group if Pplat>32. Adjusted Cox regression model: HR 0.68 (95% CI, 0.48 to 0.98; p=.04) Adjustments made for PaO2/FiO2; Pplat, SAPS II

  11. Open Lung Strategy:Metaanalysis: High vs Low PEEP. • Higher PEEP (n=1136) Low PEEP (n=1163) • Higher PEEP: better PaO2 transiently (same at day 7) • Higher PEEP:  Pplat; PEEP Briel et al. JAMA. 2010

  12. Why these results? Responders Nonresponders Grasso et al. High vs Low PEEP. AJRCCM. 2005.

  13. HFO: The perfect scenario Risk of overdistension injury Lung volume Risk of atelectasis injury Time

  14. Avoid this Risk of overdistension injury Lung volume Risk of atelectasis injury Time

  15. HFOV: Our curiosity with this mode has come to an end • OSCILLATE trial • 548 patients • HFO group • Increased sedation/paralytics • More pressors/high mean airway pressures • Less refractory hypoxemia • Increased mortality? N=146 P=.08 Ferguson et al. NEJM. 2013

  16. Prone Positioning in ARDS: Mount Everest in Kansas • Recruited more severely hypoxemic patients • Prone group with higher PaO2:FiO2 ratio at days 3 and 5 • Prone group had lower Pplatrs lower at days 3 and 5 • NNT to prevent one death was 6 Guerin et al. NEJM. 2013

  17. Pleural pressure in dependent and non-dependent regions Fessler and Talmor. Respiratory Care. 2010

  18. APRV: Evidence & Limitations • Evidence • Limited, small, mostly trauma patients • One RCT: APRV vs LOVT • Intubated trauma patients at risk for ARDS • LOVT = SIMV (VT = 6ml/kg PS=10 cm H20) • Limitations • At Phigh: spont breaths can add to strech • Plow to Phigh: shearing/atelectrauma N=31 N=32 Maxwell et al. J Trauma. 2010

  19. ↑ Mean Airway Pressure ≠ ↑ PaO2/FiO2

  20. Conclusions • 2 decades of extensive prospective studies • APRV = 1 very small RCT (negative study) • Longer time on ventilator • No improvements in oxygenation • Trend towards more sedation! • Low tidal volume ventilation is GOLD STANDARD • Severe cases • Neuromuscular blockage • Prone ventilation • Neither requires tertiary care center/ high technology

  21. Sage Advice from the master